These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38031801)

  • 1. Use of the Second Revision of the International Staging System for prognostic stratification of multiple myeloma patients in real-world clinical practice and the importance of sub-groups, including age.
    Uesugi Y; Ikeda D; Fukumoto A; Tabata R; Miura D; Narita K; Takeuchi M; Matsue K
    Haematologica; 2024 May; 109(5):1593-1597. PubMed ID: 38031801
    [No Abstract]   [Full Text] [Related]  

  • 2. A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System.
    Jung SH; Kim K; Kim JS; Kim SJ; Cheong JW; Kim SJ; Ahn JS; Ahn SY; Yang DH; Kim HJ; Lee JJ
    Br J Haematol; 2018 Jun; 181(5):707-710. PubMed ID: 28466549
    [No Abstract]   [Full Text] [Related]  

  • 3. Is the revised International staging system for myeloma valid in a real world population?
    Walker I; Coady A; Neat M; Ladon D; Benjamin R; El-Najjar I; Kazmi M; Schey S; Streetly M
    Br J Haematol; 2018 Feb; 180(3):451-454. PubMed ID: 27734463
    [No Abstract]   [Full Text] [Related]  

  • 4. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
    Bila J; Jelicic J; Dencic Fekete M; Trajkovic G; Sretenovic A; Perunicic Jovanovic M; Antic D; Mihaljevic B
    Oncol Res Treat; 2017; 40(10):616-620. PubMed ID: 28950269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis.
    Chen H; Zhou N; Hu X; Wang D; Wei W; Peng R; Chen X; Shi H; Wu L; Yu W; Zhao W; Zhou F
    Hematol Oncol; 2023 Feb; 41(1):139-146. PubMed ID: 36252280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
    Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma.
    Hungria VT; Maiolino A; Martinez G; Colleoni GW; Coelho EO; Rocha L; Nunes R; Bittencourt R; Oliveira LC; Faria RM; Pasquini R; Magalhães SM; Souza CA; Pinto Neto JV; Barreto L; Andrade E; Portella Mdo S; Bolejack V; Durie BG;
    Haematologica; 2008 May; 93(5):791-2. PubMed ID: 18450738
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
    Mihou D; Katodritou E; Zervas K
    Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a prognostic model for overall survival in multiple myeloma using the Connect
    Terebelo HR; Abonour R; Gasparetto CJ; Toomey K; Durie BGM; Hardin JW; Jagannath S; Wagner L; Narang M; Flick ED; Srinivasan S; Yue L; Kitali A; Agarwal A; Rifkin RM;
    Br J Haematol; 2019 Dec; 187(5):602-614. PubMed ID: 31382320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
    Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
    Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
    González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R
    Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents.
    Iriuchishima H; Saitoh T; Handa H; Isoda A; Matsumoto M; Sawamura M; Iwasaki A; Ushie C; Hattori H; Sasaki Y; Mitsui T; Yokohama A; Tsukamoto N; Murakami H; Nojima Y
    Eur J Haematol; 2015 Feb; 94(2):145-51. PubMed ID: 24981274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
    Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International staging system for multiple myeloma.
    Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
    J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Screening of prognostic factors and comparing of staging systems of multiple myeloma].
    Li J; Wu XB; Zhou Y; Wang X; Chen JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):926-9. PubMed ID: 22931656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of the Second Revision of the International Staging System (R2-ISS) in the prognostic assessment of newly diagnosed multiple myeloma].
    Yan J; Zhou DM; Shao XY; Xu Y; Chen B
    Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):170-177. PubMed ID: 38604794
    [No Abstract]   [Full Text] [Related]  

  • 17. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.
    Rajkumar SV; Buadi F
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):665-80. PubMed ID: 18070712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma.
    Yan W; Fan H; Xu J; Liu J; Li L; Du C; Deng S; Sui W; Xu Y; Zou D; Qiu L; An G
    Chin Med J (Engl); 2023 Jul; 136(14):1744-1746. PubMed ID: 37306432
    [No Abstract]   [Full Text] [Related]  

  • 19. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
    Waheed S; Shaughnessy JD; van Rhee F; Alsayed Y; Nair B; Anaissie E; Szymonifka J; Hoering A; Crowley J; Barlogie B
    Cancer; 2011 Mar; 117(5):1001-9. PubMed ID: 20945320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma.
    Tandon N; Rajkumar SV; LaPlant B; Pettinger A; Lacy MQ; Dispenzieri A; Buadi FK; Gertz MA; Hayman SR; Leung N; Go RS; Dingli D; Kapoor P; Lin Y; Hwa YL; Fonder AL; Hobbs MA; Zeldenrust SR; Lust JA; Gonsalves WI; Russell SJ; Kumar SK
    Blood Cancer J; 2017 Feb; 7(2):e528. PubMed ID: 28211889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.